Kymera Therapeutics, Inc. (KYMR)
US — Healthcare Sector
Automate Your Wheel Strategy on KYMR
With Tiblio's Option Bot, you can configure your own wheel strategy including KYMR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KYMR
- Rev/Share 0.501
- Book/Share 10.8391
- PB 8.2719
- Debt/Equity 0.0888
- CurrentRatio 7.381
- ROIC -0.3182
- MktCap 6450949761.0
- FreeCF/Share -2.637
- PFCF -28.0224
- PE -26.5224
- Debt/Assets 0.0762
- DivYield 0
- ROE -0.3335
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | KYMR | Guggenheim | -- | Buy | -- | $90 | Nov. 3, 2025 |
| Reiterated | KYMR | B. Riley Securities | -- | Buy | $60 | $80 | Oct. 24, 2025 |
| Initiation | KYMR | Mizuho | -- | Outperform | -- | $81 | Oct. 21, 2025 |
| Reiterated | KYMR | H.C. Wainwright | -- | Buy | $60 | $70 | Sept. 18, 2025 |
| Initiation | KYMR | Barclays | -- | Overweight | -- | $60 | Sept. 17, 2025 |
| Initiation | KYMR | RBC Capital Mkts | -- | Outperform | -- | $70 | Sept. 16, 2025 |
| Resumed | KYMR | B. Riley Securities | -- | Buy | -- | $60 | July 30, 2025 |
| Resumed | KYMR | Morgan Stanley | -- | Overweight | -- | $70 | July 3, 2025 |
| Upgrade | KYMR | B. Riley Securities | Neutral | Buy | -- | $60 | June 3, 2025 |
| Upgrade | KYMR | Morgan Stanley | Equal Weight | Overweight | -- | $79 | June 3, 2025 |
News
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
KYMR
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
Read More
About Kymera Therapeutics, Inc. (KYMR)
- IPO Date 2020-08-21
- Website https://www.kymeratx.com
- Industry Biotechnology
- CEO Nello Mainolfi
- Employees 208
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.